Anatabine Supplementation Presented at Neuroscience 2012
Participants at a conference on the predicted prevalence of Alzheimer’s disease were advised by Michael Mullan, head of the Roskamp Institute in Sarasota, that a combination of dietary factors had massive significance in the offset of the threat of Alzheimer’s disease. He stresses that the high intake of foods such as olive oil, fruits and vegetables and even a moderate level of alcohol is a welcome factor in the prevention of the disease. Mullan stressed that aggressive medical control of disorders such as diabetes, cardiac disease and abnormal levels of lipids, i.e. high cholesterol, must be controlled in order not to aggravate the onset of the symptoms.
Guest Column on heraldtribune
Recent failure by leading pharmaceutical companies in separate trials held for the treatment of Alzheimer’s disease has unfortunately reduced optimism for an imminent treatment for the disease. Vaccines by Eli Lilly and Elan/Pfizer/Johnson & Johnson failed to produce an encouraging effect in treatment of the disease. Michael Mullan, head of the Roskamp Institute in Sarasota, which primarily researches new treatments for Alzheimer’s disease, feels that the Amyloid itself must be prevented from depositing in the brain and aiming for the late stages of the disease rather than the early stages may be the wrong approach. Mullan expressed that a local and nationwide commitment to research of Alzheimer’s should be adopted as well as more funding.
What the Roskamp Institute is all about
At the beginning of this year, a breakthrough in the scientific endeavor to overcome Alzheimer’s disease occurred. NILVAD, a research collaboration involving participants from UK, Ireland, France, Germany, Sweden, Italy, Hungary, Greece and the Netherlands, launched a large scale phase III clinical trial to evaluate the efficacy of Nilvadipine in around 500 Alzheimer’s patients. With only eight phase III trials being conducted globally this is a huge accomplishment for the Roskamp Institute, headed by Michael Mullan, whose team discovered that Nilvadipine, which is approved in Europe for treatment of hypertension, can stop the accumulation of the toxic Amyloid protein in the brain.
Alzheimer’s test in Sarasota , Florida
Alzheimer’s research is currently moving rapidly and a European large-scale Alzheimer’s clinical trial is now getting under way to test the efficacy of Nilvadipine. With the involvement of nine European countries in the study consisting of 500-patients, Michael Mullan, CEO of the Roskamp Institute advises that the rationale behind the treatment is that it is an Amyloid lowering drug stopping the accumulation of Amyloid is likely to halt or slow the disease. The Roskamp Institute’s researchers initially tested Nilvadipine in animals and since 1996 it has been studied for its ability to clear away Amyloid plaque and to increase blood flow to the brain.
Promising results for anatabine supplementation in reducing inflammation and in an animal model
Recently, Roskamp Institute researchers led by Dr Michael Mullan revealed several beneficial effects of a naturally occurring compound derived from the tobacco plant. The latest findings show that the nutraceutical, Anatabine, considerably improves memory and also reduces central and peripheral inflammation in mice that were bred to have the brain disease – Alzheimer’s. Other findings show the effects of Anatabine in mice with experimental autoimmune encephalomyelitis which is a model of Multiple Sclerosis. Finally, research on Anatabine supplementation in easing recovery from traumatic brain injury (TBI) was revealed at the recent annual meeting of the Society for Neuroscience ‘Neuroscience 2012’, the foremost venue for neuroscientists from around the globe to unveil advanced research relating to the nervous system and the brain.
A cure in our time
The brain disease research center in Sarasota, Florida, the Roskamp Institute, led by Michael Mullan have begun clinical trials on Nilvadipine which researchers hope will bring the end to Alzheimer’s disease. Nilvadipine is administered in the treatment of hypertension but its anti-inflammatory properties have been found affective in destroying the source of the disease, the Amyloid proteins in the form of plaque that build up in the brain, killing healthy neurons. Dr Mullan is also exploring other potential therapies like Anatabine supplementation, derived from tobacco and developed by the Roskamp Institute.
bringing Jackson Labs to Southwest Florida.
The team at Roskamp Institute is working hard on the development of Nilvadipine, which has European and Japanese approval for the indication of treatment of hypertension and have discovered that Nilvadipine can ease the accumulation of Amyloid proteins, the cause of Alzheimer’s disease. Dr Michael Mullan specifically raised Archer Pharmaceuticals, who hold the license for use of Nilvadipine in the US in the treatment of Alzheimer’s, in order to commercialize use of the drug and to develop other drugs to observe the method how Nilvadipine acts in the brain. Nilvadipine has already been approved for safety with Alzheimer’s patients and has moved to Phase 3 of clinical trials testing.
Roskamp requires more benefactors
The Roskamp Institute is a first class facility equipped with state of the art equipment and is located on land worth around $40 million. Scientists who work there come from all across the globe and an advantage of working at the Institute unlike other universities, is that researchers do not waste any time teaching so are completely focused on their research. The Institute’s director is Dr Michael Mullan, a British researcher and psychiatrist, who before arriving in Florida, was famed for leading a London team in the 1990’s and making the discovery of the first genetic cause of Alzheimer’s disease.
A step forward in Alzheimer’s research
Researchers at the Roskamp Institute in Sarasota are working nonstop with regards to stopping inflammation and Amyloid growth which they believe is associated with the degenerative brain illness – Alzheimer’s disease. Discovery of the receptor on nerve cells, known as CXCR2, is the location where the Amyloid-creating reaction occurs and if interruption of Amyloid production is carried out, reduction of Amyloid can be achieved. These findings that point to a rotation, where inflammation is responsible for creation of increased Amyloid production, causing more inflammation were published in the 9th December, 2008 edition of a publication of the American Chemical Society.
In vivo testing to be done in sarasota
Principal head of the Roskamp Institute, Dr Michael Mullan, told an audience at a long-term care center in Sarasota of the optimism in finding a cure in the treatment of Alzheimer’s disease and other brain degenerative conditions. The crowd consisted mainly of nurses, social workers and family relations of patients suffering from these conditions and Dr Mullan updated them with regards to a safety study that had been conducted in Ireland. Treatment of Nilvadipine in the elderly had shown almost no side effects and he spoke of the intent to carry out longer-term studies in the USA examining tolerance of variation of levels of Nilvadipine.